An overview of sphingosine-1-phosphate receptor 2: Structure, biological function, and small-molecule modulators

被引:2
作者
Hao, Wanting [1 ]
Luo, Dongdong [1 ]
Jiang, Yuqi [1 ]
Wan, Shengbiao [1 ]
Li, Xiaoyang [1 ,2 ]
机构
[1] Ocean Univ China, Sch Med & Pharm, Lab Marine Drugs, Chinese Minist Educ, Qingdao 266003, Peoples R China
[2] Inst Qingdao, Marine Biomed Res, Qingdao, Peoples R China
基金
中国国家自然科学基金;
关键词
agonists; antagonists; biological function; G-protein-coupled receptor; sphingosine-1-phosphate receptor 2; SPHINGOSINE; 1-PHOSPHATE; BILE-ACIDS; SIGNALING PATHWAY; RATIONAL DESIGN; G-PROTEINS; BONE LOSS; S1PR2; DISCOVERY; ACTIVATION; FTY720;
D O I
10.1002/med.22044
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Over the past decade, there has been a notable increase in research on sphingosine-1-phosphate receptor 2 (S1PR2), which is a type of G-protein-coupled receptor. Upon activation by S1P or other ligands, S1PR2 initiates downstream signaling pathways such as phosphoinositide 3-kinase (PI3K), Mitogen-activated protein kinase (MAPK), Rho/Rho-associated coiled-coil containing kinases (ROCK), and others, contributing to the diverse biological functions of S1PR2 and playing a pivotal role in various physiological processes and disease progressions, such as multiple sclerosis, fibrosis, inflammation, and tumors. Due to the extensive biological functions of S1PR2, many S1PR2 modulators, including agonists and antagonists, have been developed and discovered by pharmaceutical companies (e.g., Novartis and Galapagos NV) and academic medicinal chemists for disease diagnosis and treatment. However, few reviews have been published that comprehensively overview the functions and regulators of S1PR2. Herein, we provide an in-depth review of the advances in the function of S1PR2 and its modulators. We first summarize the structure and biological function of S1PR2 and its pathological role in human diseases. We then focus on the discovery approach, design strategy, development process, and biomedical application of S1PR2 modulators. Additionally, we outline the major challenges and future directions in this field. Our comprehensive review will aid in the discovery and development of more effective and clinically applicable S1PR2 modulators.
引用
收藏
页码:2331 / 2362
页数:32
相关论文
共 132 条
  • [1] Mechanisms of differential desensitization of metabotropic glutamate receptors
    Abreu, Nohely
    Acosta-Ruiz, Amanda
    Xiang, Guoqing
    Levitz, Joshua
    [J]. CELL REPORTS, 2021, 35 (04):
  • [2] Sphingosine-1-phosphate receptor 2
    Adada, Mohamad
    Canals, Daniel
    Hannun, Yusuf A.
    Obeid, Lina M.
    [J]. FEBS JOURNAL, 2013, 280 (24) : 6354 - 6366
  • [3] Siponimod: First Global Approval
    Al-Salama, Zaina T.
    [J]. DRUGS, 2019, 79 (09) : 1009 - 1015
  • [4] S1PR2 deficiency in DLBCL: a FOXy connection
    Baldari, Cosima T.
    [J]. BLOOD, 2016, 127 (11) : 1380 - 1381
  • [5] Bracco I., 2011, JTE013 ANALOGS METHO, Patent No. WO2011159864A1
  • [6] Bone loss in patients with inflammatory bowel disease: cause, detection and treatment
    Bravenboer, Nathalie
    Oostlander, Angela E.
    van Bodegraven, Adriaan A.
    [J]. CURRENT OPINION IN GASTROENTEROLOGY, 2021, 37 (02) : 128 - 134
  • [7] JNK signalling in cancer: in need of new, smarter therapeutic targets
    Bubici, Concetta
    Papa, Salvatore
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (01) : 24 - 37
  • [8] Macrophage migration inhibitory factor: A regulator of innate immunity
    Calandra, T
    Roger, T
    [J]. NATURE REVIEWS IMMUNOLOGY, 2003, 3 (10) : 791 - 800
  • [9] Targeting G protein-coupled receptor signalling by blocking G proteins
    Campbell, Adrian P.
    Smrcka, Alan V.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (11) : 789 - 803
  • [10] Transmembrane protein CD69 acts as an S1PR1 agonist
    Chen, Hongwen
    Qin, Yu
    Chou, Marissa
    Cyster, Jason G.
    Li, Xiaochun
    Sohn, Jungsan
    [J]. ELIFE, 2023, 12